Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN: The HER-2 receptor and breast cancer: ten years of targeted anti–HER-2 therapy and personalized medicine. Oncologist. 2009, 14: 320-368. 10.1634/theoncologist.2008-0230.
Article
CAS
PubMed
Google Scholar
Wilken JA, Badri T, Cross S, Raji R, Santin AD, Schwartz P, Branscum AJ, Baron AT, Sakhitab AI, Maihle NJ: EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem. 2012, 4: 447-469. 10.4155/fmc.12.11.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lorenzen S, Lordick F: How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?. Curr Opin Oncol. 2011, 23: 396-402. 10.1097/CCO.0b013e3283469567.
Article
CAS
PubMed
Google Scholar
Lollini PL, Cavallo F, Nanni P, Forni G: Vaccines for tumour prevention. Nat Rev Cancer. 2006, 6: 204-216. 10.1038/nrc1815.
Article
CAS
PubMed
Google Scholar
Lollini PL, Nicoletti G, Landuzzi L, Cavallo F, Forni G, De Giovanni C, Nanni P: Vaccines and other immunological approaches for cancer immunoprevention. Curr Drug Targets. 2011, 12: 1957-1973. 10.2174/138945011798184146.
Article
CAS
PubMed
Google Scholar
Farkas AM, Finn OJ: Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulation. Semin Immunol. 2010, 22: 125-131. 10.1016/j.smim.2010.03.003.
Article
CAS
PubMed
Google Scholar
Ladjemi MZ, Jacot W, Chardès T, Pèlegrin A, Navarro-Teulon I: Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother. 2010, 59: 1295-1312. 10.1007/s00262-010-0869-2.
Article
CAS
PubMed
PubMed Central
Google Scholar
Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M: HER-2/neu as a target for cancer vaccines. Immunotherapy. 2010, 2: 213-226. 10.2217/imt.09.89.
Article
CAS
PubMed
Google Scholar
Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Koski G, Czerniecki BJ: HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer. 2012, 118: 4354-4362. 10.1002/cncr.26734.
Article
CAS
PubMed
PubMed Central
Google Scholar
Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C, Bouchard P, Wolf S, Modesti A, Musiani P, Lollini PL, Colombo MP, Forni G: Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med. 1998, 188: 589-596. 10.1084/jem.188.3.589.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F, Pupa SM, Rossi I, Colombo MP, Ricci C, Astolfi A, Musiani P, Forni G, Lollini PL: Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med. 2001, 194: 1195-1205. 10.1084/jem.194.9.1195.
Article
CAS
PubMed
PubMed Central
Google Scholar
De Giovanni C, Nicoletti G, Landuzzi L, Astolfi A, Croci S, Comes A, Ferrini S, Meazza R, Iezzi M, Di Carlo E, Musiani P, Cavallo F, Nanni P, Lollini PL: Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res. 2004, 64: 4001-4009. 10.1158/0008-5472.CAN-03-2984.
Article
CAS
PubMed
Google Scholar
Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Antognoli A, Landuzzi L, Fabbi M, Ferrini S, Musiani P, Iezzi M, De Giovanni C, Lollini PL: Antimetastatic activity of a preventive cancer vaccine. Cancer Res. 2007, 67: 11037-11044. 10.1158/0008-5472.CAN-07-2499.
Article
CAS
PubMed
Google Scholar
Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E, Pupa SM, De Giovanni C, Spadaro M, Curcio C, Lollini PL, Musiani P, Forni G, Cavallo F: Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res. 2004, 64: 2858-2864. 10.1158/0008-5472.CAN-03-2962.
Article
CAS
PubMed
Google Scholar
De Giovanni C, Nicoletti G, Palladini A, Croci S, Landuzzi L, Antognoli A, Murgo A, Astolfi A, Ferrini S, Fabbi M, Orengo AM, Amici A, Penichet ML, Aurisicchio L, Iezzi M, Musiani P, Nanni P, Lollini PL: A multi-DNA preventive vaccine for p53/neu-driven cancer syndrome. Hum Gene Ther. 2009, 20: 453-464. 10.1089/hum.2008.172.
Article
CAS
PubMed
Google Scholar
Quaglino E, Mastini C, Amici A, Marchini C, Iezzi M, Lanzardo S, De Giovanni C, Montani M, Lollini PL, Masucci G, Forni G, Cavallo F: A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res. 2010, 70: 2604-2612. 10.1158/0008-5472.CAN-09-2548.
Article
CAS
PubMed
Google Scholar
Piechocki MP, Ho YS, Pilon S, Wei WZ: Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J Immunol. 2003, 171: 5787-5794.
Article
CAS
PubMed
Google Scholar
Jacob JB, Quaglino E, Radkevich-Brown O, Jones RF, Piechocki MP, Reyes JD, Weise A, Amici A, Wei WZ: Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity. Cancer Res. 2010, 70: 119-128. 10.1158/0008-5472.CAN-09-2554.
Article
CAS
PubMed
PubMed Central
Google Scholar
Finkle D, Quan ZR, Asghari V, Kloss J, Ghaboosi N, Mai E, Wong WL, Hollingshead P, Schwall R, Koeppen H, Erickson S: HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res. 2004, 10: 2499-2511. 10.1158/1078-0432.CCR-03-0448.
Article
CAS
PubMed
Google Scholar
Ladjemi MZ, Chardes T, Corgnac S, Garambois V, Morisseau S, Robert B, Bascoul-Mollevi C, Ait Arsa I, Jacot W, Pouget JP, Pelegrin A, Navarro-Teulon I: Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice. Breast Cancer Res. 2011, 13: R17-10.1186/bcr2826.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Ianzano ML, Grosso V, Stivani V, Antognoli A, Lamolinara A, Landuzzi L, di Tomaso E, Iezzi M, De Giovanni C, Lollini PL: Multiorgan metastasis of human HER-2+ breast cancer in Rag2−/−;Il2rg−/− mice and treatment with PI3K inhibitor. PLoS One. 2012, 7: e39626-10.1371/journal.pone.0039626.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nanni P, Nicoletti G, Landuzzi L, Croci S, Murgo A, Palladini A, Antognoli A, Ianzano ML, Stivani V, Grosso V, Maira SM, García-Echeverría C, Scotlandi K, De Giovanni C, Lollini PL: High metastatic efficiency of human sarcoma cells in Rag2/γc double knockout mice provides a powerful test system for antimetastatic targeted therapy. Eur J Cancer. 2010, 46: 659-668. 10.1016/j.ejca.2009.11.018.
Article
CAS
PubMed
Google Scholar
Palladini A, Nicoletti G, Pappalardo F, Murgo A, Grosso V, Stivani V, Ianzano ML, Antognoli A, Croci S, Landuzzi L, De Giovanni C, Nanni P, Motta S, Lollini PL: In silico modeling and in vivo efficacy of cancer-preventive vaccinations. Cancer Res. 2010, 70: 7755-7763. 10.1158/0008-5472.CAN-10-0701.
Article
CAS
PubMed
Google Scholar
Marchini C, Gabrielli F, Iezzi M, Zenobi S, Montani M, Pietrella L, Kalogris C, Rossini A, Ciravolo V, Castagnoli L, Tagliabue E, Pupa SM, Musiani P, Monaci P, Menard S, Amici A: The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse. PLoS One. 2011, 6: e18727-10.1371/journal.pone.0018727.
Article
CAS
PubMed
PubMed Central
Google Scholar
Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ: Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA. 1992, 89: 10578-10582. 10.1073/pnas.89.22.10578.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nanni P, Landuzzi L, Nicoletti G, De Giovanni C, Rossi I, Croci S, Astolfi A, Iezzi M, Di Carlo E, Musiani P, Forni G, Lollini PL: Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-γ and B cell dependent. J Immunol. 2004, 173: 2288-2296.
Article
CAS
PubMed
Google Scholar
Nanni P, Gatta V, Menotti L, De Giovanni C, Ianzano M, Palladini A, Grosso V, Dall’ora M, Croci S, Nicoletti G, Landuzzi L, Iezzi M, Campadelli-Fiume G, Lollini PL: Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. PLoS Pathog. 2013, 9: e1003155-10.1371/journal.ppat.1003155.
Article
CAS
PubMed
PubMed Central
Google Scholar
Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, Knutson KL, Bergh J, Lidbrink E, Kiessling R: Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med. 2010, 8: 53-10.1186/1479-5876-8-53.
Article
PubMed
PubMed Central
Google Scholar
Rolla S, Nicoló C, Malinarich S, Orsini M, Forni G, Cavallo F, Ria F: Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol. 2006, 177: 7626-7633.
Article
CAS
PubMed
Google Scholar